BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Metformin for treatment of type 2 diabetes: use is extended to patients with moderately reduced kidney function

2016.11.03

Active substance: metformin

As of 14 October 2016 and based on a European safety review, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended further lowering the limit of the creatinine clearance above which metformin is contraindicated.

For details regarding the procedure please click on the following link to the European Medicines Agency (EMA):

Metformin and metformin-containing medicines